Clinical trials: Memory Disorders
Cognitive Dysfunction, Memory Disorders
A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease
The purpose of this study is to test the use of a screening tool to detect changes in the eye that are associated with Alzheimer's disease in adult participants with memory issues.
- Trial name
- NCT07254234
- Testing
- Retinal scan, Blood test
- Where
- 3 sites in United Arab Emirates
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Mild Cognitive Impairment
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
- Trial name
- NCT05469360
- Testing
- NIO752
- Where
- 10 sites in Finland, France and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Difficulty Focusing, Poor Concentration
A Clinical Trial to Evaluate the Effects of a Supplement on Children's Focus and Energy
This study will evaluate the effects of the Auri Super Mushroom Daily Gummies For Kids on focus and energy in children aged 4-12.
- Conditions
- Difficulty Focusing, Poor Concentration, Poor Memory, Low Energy
- Trial name
- NCT07766642
- Testing
- Auri Super Mushroom Daily Gummies For Kids
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Auri Nutrition
Healthy, Memory Problems
A Clinical Trial to Examine Lysoveta on Cognitive Function in Healthy Adults With Self-perceived Memory Problems
The study is a randomized, placebo-controlled, triple-blind, parallel group trial, in which the effect of krill oil is investigated in healthy volunteers with self-perceived memory problems.
- Trial name
- NCT07034794
- Testing
- Lysoveta
- Where
- Canada
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Aker BioMarine Human Ingredients AS
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Alzheimer's Disease, Early Alzheimer's Disease
A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's Disease
The purpose of this study is to compare the results of two different sleep tests in Alzheimer's patients with no symptoms or early symptoms.
- Conditions
- Alzheimer's Disease, Early Alzheimer's Disease, Memory Problems
- Trial name
- NCT07485153
- Testing
- Mobile EEG, Activity Monitor, Sleep Study
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early…
- Trial name
- ALTITUDE-AD (NCT06335173)
- Testing
- sabirnetug
- Where
- 68 sites in United States, Canada and 3 more
- Volunteers
- 542 people
- Sponsor
- Acumen Pharmaceuticals
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Dementia, Dementia Alzheimer Type
Plans4Care: Personalized Dementia Care on Demand
The Plans4Care study is a research study funded by the National Institute on Aging (Grant# R44AG084365). The Plans4Care app is designed to help family caregivers address over 90 common care challenges such as behavioral symptoms…
- Conditions
- Dementia, Dementia Alzheimer Type, Alzheimer Dementia (AD), Memory Loss
- Trial name
- NCT07115251
- Testing
- Plans4Care
- Volunteers
- 160 people
- Sponsor
- Plans4Care Inc
Memory Disorders, Postmenopausal Symptoms
The Effect of a Multivitamin in the Treatment of Memory Loss in Postmenopausal Women
Complaints about memory loss are very common in women in the menopausal transition period. The effectiveness of estrogen replacement therapy in cognitive improvement is controversial.
- Trial name
- NCT03835325
- Testing
- Cogmax®
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eurofarma Laboratorios S.A.
Mild Alzheimer's Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease
The purpose of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with Mild Alzheimer's Disease.
- Trial name
- NCT03186989
- Testing
- IONIS MAPTRx
- Where
- 13 sites in Canada, Finland and 4 more
- Volunteers
- 46 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP II (NCT06025877)
- Testing
- PrecivityAD2(TM) blood test
- Where
- 9 sites in United States
- Volunteers
- 400 people
- Sponsor
- C2N Diagnostics
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
The proposed study is designed to evaluate the performance of the ALTOIDA™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Disorders, Cognitive Impairment
- Trial name
- AltoidaML (NCT02843529)
- Testing
- Altoida: neuropsychological, MRI, EEG and CSF biomarkers
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Altoida
Healthy Participants, Healthy Population
Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants
The present study aims to assess the safety and feasibility of repeated transcranial alternating current stimulation (tACS) by the Miamind Neurostimulator in a cohort of healthy participants.
- Trial name
- MindStim (NCT05999916)
- Testing
- Personalized Miamind Neurostimulator
- Where
- Switzerland
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bottneuro AG
Memory Deficits, Cognitive Change
An Exploratory Investigation of a Supplement to Promote Brain Health
Providing a combination of synergistic dietary supplements, such as vitamins B6, B12, and folate, as well as curcumin, lemon balm, and American ginseng is hypothesized to promote brain health and aid with brain fog, mental…
- Conditions
- Memory Deficits, Cognitive Change, Stress
- Trial name
- NCT05520424
- Testing
- The Daily Supplement
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Parable
Memory Impairment, Dementia, Vascular
CognivAiD Real-World Evidence Clinical Registry (CONNECT Registry)
This is an observational, prospective cohort of patients who were prescribed or have taken CognivAiD as prescribed by the attending physician. The safety and efficacy of CognivAiD have been established in clinical studies.
- Trial name
- CONNECT (NCT06228638)
- Testing
- CognivAID (Sailuotong)
- Where
- Singapore
- Volunteers
- 100 people
- Sponsor
- Moleac Pte Ltd.
Memory Impairment, Age-related Cognitive Decline
Development of an Innovative Health Ingredient From Marine By-products for the Healthy Aging
This interventional, randomised, placebo-controlled and double-blind study aims to evaluate the effect of a dietary supplementation with a blue fish hydrolysate derived from marine by-products, containing peptides and n-3…
- Trial name
- BRAINBOOSTER (NCT04910399)
- Testing
- Blue fish hydrolysate
- Where
- 2 sites in France
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Abyss Ingredients
Alzheimer Disease
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the safety and efficacy of masitinib for the treatment of mild to moderate Alzheimer's Disease.
- Trial name
- NCT01872598
- Testing
- Masitinib, Standard of care
- Where
- 6 sites in Bulgaria, Greece and 4 more
- Volunteers
- 721 people
- Sponsor
- AB Science
Alzheimer Disease, Dementia of Alzheimer Type
A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.
- Trial name
- ACT-AD (NCT04491006)
- Testing
- ATH-1017
- Where
- 13 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- LeonaBio